Latest news
Takeda Targets High-Need Psoriasis Niche With New Phase 3b Zasocitinib Study - TipRanksTipRanks · Fri, 07 Aug 2026 19:04:12 GMTTakeda’s Brazil IBD Study Wraps Up, Offering Fresh Clues on Vedolizumab Performance - TipRanksTipRanks · Fri, 07 Aug 2026 18:43:53 GMTTakeda’s LIVTENCITY CMV Study in Japan: What Investors Should Watch - TipRanksTipRanks · Fri, 07 Aug 2026 16:38:26 GMTTakeda Narcolepsy Drug Approval Highlights Beacon Biosignals Partnership - TipRanksTipRanks · Fri, 07 Aug 2026 02:38:24 GMTTakeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1 - TipRanksTipRanks · Thu, 06 Aug 2026 01:23:12 GMTFDA approves Takeda’s Orzeyful to treat narcolepsy type 1 - TipRanksTipRanks · Wed, 05 Aug 2026 23:39:41 GMTFDA approves Takeda’s Orzeyful to treat narcolepsy type 1 in adults - TipRanksTipRanks · Wed, 05 Aug 2026 21:03:39 GMTTakeda Earnings Call: FX Tailwinds, Pipeline Firepower - TipRanksTipRanks · Wed, 05 Aug 2026 00:55:05 GMT